VivoSeq
Hematology

Von Willebrand Disease, Type 3

4

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Von Willebrand Disease, Type 3 is an early-stage landscape with 4 programs across 1 company. The most active players are Roche. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

5 programs

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 34

Emicizumab

Roche

Von Willebrand Factor Concentrates

Roche

Factor VIII Concentrates

Roche

Bypassing Agents

Roche

Approved
No programs

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Recruiting1 · 50%

Clinical Trials

Trial Activity

A Multicenter Non-Interventional Study Evaluating Bleeds and Health-Related Quality Of Life in Patients With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
Active, not recruiting·Roche logoRoche·N/A·NCT06883240·44 enrolled
A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients With Type 3 Von Willebrand Disease
Recruiting·Roche logoRoche·Phase 3·NCT06998524·75 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)